The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

These filings mark the beginning of sonro's evolution and a potential game-changing therapy across multiple B-cell malignancies ... to see listing in the NCCN guidelines. And also more recently ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

Multiple myeloma is a disease that most people haven’t heard of until it impacts their lives directly. This blood cancer can sound daunting but understanding it is the first step towards ...

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

A long-term study shows no survival advantage for a second transplant in relapsed myeloma, challenging traditional treatment ...